Mirati Therapeutics (MRTX) 8.09 $MRTX
Mirati Therapeutics Provides Progress Update On Current Clinical Trials
PR Newswire - Sun Jun 05, 8:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 11:00 a.m. ET (8:00 a.m. PT) in New York.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present Abstracts On Pipeline Programs At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thu May 19, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that abstracts on its investigational tyrosine kinase inhibitor candidates, glesatinib (MGCD265) and sitravatinib (MGCD516), will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL from June 3-7, 2016.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Reports Financial Results And Business Update For The First Quarter 2016
PR Newswire - Thu May 05, 3:15PM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2016 and provided an update on its product development programs.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present Preclinical Data At 2016 American Association For Cancer Research Annual Meeting
PR Newswire - Thu Mar 24, 7:30AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced it will present preclinical data on two of its three oncology therapies currently in development. Data on glesatinib (MGCD265), its tyrosine kinase inhibitor targeting MET and Axl; and mocetinostat (MGCD103), its spectrum-selective HDAC inhibitor, will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting to be held in New Orleans, LA from April 16-20, 2016.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer
PR Newswire - Wed Mar 23, 7:30AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016.
MRTX: 8.09 (-1.53)
Mirati reports 4Q loss
Automated Insights - Wed Mar 09, 4:03PM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Wednesday reported a loss of $18.4 million in its fourth quarter.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update
PR Newswire - Wed Mar 09, 3:15PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on its drug development programs.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present At The Barclays Global Healthcare Conference
PR Newswire - Tue Mar 08, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 at 2:05 p.m. ET (11:05 a.m. PT) in Miami.
MRTX: 8.09 (-1.53)
Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial
PR Newswire - Mon Dec 21, 7:16AM CST
Guardant Health, the market leader in liquid biopsies, and Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, announced today that they have entered into a collaboration for the development of a circulating tumor DNA (ctDNA) assay for Mirati's kinase inhibitor, glesatinib.
MRTX: 8.09 (-1.53)
Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
PR Newswire - Mon Dec 21, 7:16AM CST
Foundation Medicine, Inc. (NASDAQ: FMI) and Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, today announced that they have entered into a collaboration for the development of a companion diagnostic test for glesatinib. The test, designed for use by physicians, will be used to identify NSCLC patients most likely to respond to Mirati's kinase inhibitor, glesatinib.
FMI: 18.91 (-1.17), MRTX: 8.09 (-1.53)
Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
PR Newswire - Mon Dec 21, 7:15AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265. Glesatinib is an inhibitor of the MET and Axl receptor tyrosine kinase pathways which, when altered, are drivers of tumor growth. The Phase 2 clinical trial will evaluate glesatinib in NSCLC patients with activating genetic alterations of the MET gene, including MET gene amplification and MET mutations.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients
PR Newswire - Thu Dec 17, 7:15AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD516. The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, which are known oncogenic drivers. The study will also explore other mechanisms that may play a role in regulating tumor growth, including selecting for patients with CBL mutations and chromosome 4 amplicon alterations.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference
PR Newswire - Tue Dec 01, 7:15AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. ET (6:45 a.m. PT) in New York. Charles M. Baum, M.D., Ph.D., president and CEO of Mirati, will provide a corporate overview.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
PR Newswire - Fri Nov 06, 7:15AM CST
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its drug development programs.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors
PR Newswire - Mon Sep 28, 7:00AM CDT
Mirati Therapeutics, Inc. ("Mirati" (NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it presented data from the study titled, "A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors" at the 2015 European Cancer Congress (ECC) in Vienna, Austria.
MRTX: 8.09 (-1.53)
Critical Alerts For FireEye, Mirati Therapeutics, Axovant Sciences, Shake Shack and Nabors Industries Released By InvestorsObserver
PR Newswire - Fri Sep 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, MRTX, AXON, SHAK and NBR.
AXON: 14.80 (-0.44), SHAK: 34.95 (-2.83), FEYE: 15.81 (-0.77), NBR: 10.37 (-0.37), MRTX: 8.09 (-1.53)
Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles
M2 - Wed Sep 23, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5k9pd/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - ADC Therapeutics Sarl - Affimed Therapeutics AG - Aptose Biosciences Inc. - Arbutus Biopharma Corporation - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Biogenomics Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell Medica Limited - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - Curis, Inc. - Gamida Cell Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - NantKwest, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Philogen S.p.A. - Seattle Genetics, Inc. - Selvita SA - Sigma-Tau S.p.A. - TG Therapeutics, Inc. - Theravectys SA Drug Profiles (Partial List) - abexinostat hydrochloride - Drug Profile - acalisib - Drug Profile - ADCT-301 - Drug Profile - AFM-13 - Drug Profile - Alocrest - Drug Profile - aNK Program - Drug Profile - APTO-253 - Drug Profile - azacitidine - Drug Profile - BMS-986016 - Drug Profile - BPX-501 - Drug Profile - brentuximab vedotin - Drug Profile - CBM-C30.1 - Drug Profile - Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile - Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile - Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile - Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile - Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile - CMD-003 - Drug Profile - CPI-0610 - Drug Profile - CUDC-907 - Drug Profile - Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile - INCB-40093 - Drug Profile - Indimitecan - Drug Profile - Indotecan hydrochloride - Drug Profile - interferon alfa-2b (recombinant) - Drug Profile - Iomab-B - Drug Profile - NSC-678515 - Drug Profile - panobinostat - Drug Profile - pembrolizumab - Drug Profile - pevonedistat hydrochloride - Drug Profile - procarbazine hydrochloride - Drug Profile - radretumab - Drug Profile - Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile - TGR-1202 - Drug Profile - TKM-PLK1 - Drug Profile For more information visit http://www.researchandmarkets.com/research/x5...n_lymphoma
CRIS: 1.69 (-0.10), PCYC: 261.25 (+1.70), PFE: 35.29 (-0.02), INCY: 80.41 (-1.20), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), ABUS: 3.60 (-0.33), JNJ: 117.01 (+0.01), APTO: 2.96 (-0.12), ATNM: 1.82 (unch), BLCM: 12.91 (-0.03), SGEN: 40.38 (-0.63), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), AVEO: 1.03 (-0.03), MRTX: 8.09 (-1.53), CBMG: 15.16 (+0.22), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Mirati Therapeutics prices public offering of 2.25m common stock
M2 - Wed Sep 16, 4:34AM CDT
Cancer treatment company Mirati Therapeutics (NasdaqCM:MRTX) said on Tuesday that it has priced an underwritten public offering of 2,250,000 shares of its common stock.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Provides Progress Update On Current Clinical Trials
PR Newswire - Sun Jun 05, 8:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today provided an update on three current ongoing clinical programs in patients with non-small cell lung cancer (NSCLC) and other solid tumors.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present At The Jefferies 2016 Healthcare Conference
PR Newswire - Wed Jun 01, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Jefferies 2016 Healthcare Conference on Wednesday, June 8, 2016 at 11:00 a.m. ET (8:00 a.m. PT) in New York.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present Abstracts On Pipeline Programs At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
PR Newswire - Thu May 19, 7:00AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that abstracts on its investigational tyrosine kinase inhibitor candidates, glesatinib (MGCD265) and sitravatinib (MGCD516), will be presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Chicago, IL from June 3-7, 2016.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Reports Financial Results And Business Update For The First Quarter 2016
PR Newswire - Thu May 05, 3:15PM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the first quarter ended March 31, 2016 and provided an update on its product development programs.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present Preclinical Data At 2016 American Association For Cancer Research Annual Meeting
PR Newswire - Thu Mar 24, 7:30AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced it will present preclinical data on two of its three oncology therapies currently in development. Data on glesatinib (MGCD265), its tyrosine kinase inhibitor targeting MET and Axl; and mocetinostat (MGCD103), its spectrum-selective HDAC inhibitor, will be presented at the 2016 American Association for Cancer Research (AACR) Annual Meeting to be held in New Orleans, LA from April 16-20, 2016.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Announces Promotion Of Jamie A. Donadio To Chief Financial Officer
PR Newswire - Wed Mar 23, 7:30AM CDT
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced the promotion of Jamie A. Donadio to Senior Vice President and Chief Financial Officer, effective as of March 21, 2016.
MRTX: 8.09 (-1.53)
Mirati reports 4Q loss
Automated Insights - Wed Mar 09, 4:03PM CST
SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Wednesday reported a loss of $18.4 million in its fourth quarter.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Reports Fourth Quarter And Full Year 2015 Financial Results And Provides Business Update
PR Newswire - Wed Mar 09, 3:15PM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today reported financial results for the fourth quarter and full year ended December 31, 2015 and provided an update on its drug development programs.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present At The Barclays Global Healthcare Conference
PR Newswire - Tue Mar 08, 7:00AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that Charles M. Baum, M.D., Ph.D., President and CEO of Mirati, will present a corporate overview at the Barclays Global Healthcare Conference on Tuesday, March 15, 2016 at 2:05 p.m. ET (11:05 a.m. PT) in Miami.
MRTX: 8.09 (-1.53)
Guardant Health And Mirati Therapeutics Enter Into Collaboration On Glesatinib (MGCD265) In Non Small Cell Lung Cancer (NSCLC) Trial
PR Newswire - Mon Dec 21, 7:16AM CST
Guardant Health, the market leader in liquid biopsies, and Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, announced today that they have entered into a collaboration for the development of a circulating tumor DNA (ctDNA) assay for Mirati's kinase inhibitor, glesatinib. MRTX: 8.09 (-1.53)
Foundation Medicine And Mirati Therapeutics Collaborate To Develop A Companion Diagnostic For Glesatinib (MGCD265) In Non-Small Cell Lung Cancer (NSCLC)
PR Newswire - Mon Dec 21, 7:16AM CST
Foundation Medicine, Inc. (NASDAQ: FMI) and Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX), a targeted oncology company focusing on genetic and epigenetic drivers of cancer, today announced that they have entered into a collaboration for the development of a companion diagnostic test for glesatinib. The test, designed for use by physicians, will be used to identify NSCLC patients most likely to respond to Mirati's kinase inhibitor, glesatinib. FMI: 18.91 (-1.17), MRTX: 8.09 (-1.53)
Mirati Therapeutics Initiates Glesatinib (MGCD265) Phase 2 Trial In Non-Small Cell Lung Cancer (NSCLC)
PR Newswire - Mon Dec 21, 7:15AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the Phase 2 clinical trial of glesatinib (MGCD265) has commenced. The Company also announced that "glesatinib" is the proposed generic name for MGCD265. Glesatinib is an inhibitor of the MET and Axl receptor tyrosine kinase pathways which, when altered, are drivers of tumor growth. The Phase 2 clinical trial will evaluate glesatinib in NSCLC patients with activating genetic alterations of the MET gene, including MET gene amplification and MET mutations.
MRTX: 8.09 (-1.53)
Mirati Therapeutics Doses First Patient In Expansion Cohorts Of MGCD516 Phase 1b Trial In Genetically Selected Patients
PR Newswire - Thu Dec 17, 7:15AM CST
Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the first patient with Non-Small Cell Lung Cancer (NSCLC) has been dosed in a Phase 1b clinical trial of MGCD516. The trial will evaluate select patients exhibiting genetic alterations in the tyrosine kinase signaling pathways, RET, DDR and Trk, which are known oncogenic drivers. The study will also explore other mechanisms that may play a role in regulating tumor growth, including selecting for patients with CBL mutations and chromosome 4 amplicon alterations.
MRTX: 8.09 (-1.53)
Mirati Therapeutics To Present At The Oppenheimer 26th Annual Healthcare Conference
PR Newswire - Tue Dec 01, 7:15AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) will be presenting at the Oppenheimer 26th Annual Healthcare Conference on Tuesday, December 8, 2015 at 9:45 a.m. ET (6:45 a.m. PT) in New York. Charles M. Baum, M.D., Ph.D., president and CEO of Mirati, will provide a corporate overview. MRTX: 8.09 (-1.53)
Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
PR Newswire - Fri Nov 06, 7:15AM CST
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX) today reported financial results for the third quarter ended September 30, 2015 and provided an update on its drug development programs. MRTX: 8.09 (-1.53)
Mirati Therapeutics Presents Interim Clinical Data From Ongoing MGCD516 Phase 1 Dose Escalation Study In Patients With Advanced Solid Tumors
PR Newswire - Mon Sep 28, 7:00AM CDT
Mirati Therapeutics, Inc. ("Mirati"
(NASDAQ: MRTX), an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it presented data from the study titled, "A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors" at the 2015 European Cancer Congress (ECC) in Vienna, Austria. MRTX: 8.09 (-1.53)
Critical Alerts For FireEye, Mirati Therapeutics, Axovant Sciences, Shake Shack and Nabors Industries Released By InvestorsObserver
PR Newswire - Fri Sep 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for FEYE, MRTX, AXON, SHAK and NBR.
AXON: 14.80 (-0.44), SHAK: 34.95 (-2.83), FEYE: 15.81 (-0.77), NBR: 10.37 (-0.37), MRTX: 8.09 (-1.53)
Hodgkin Lymphoma Pipeline Review, H2 2015 - 38 Companies & 57 Drug Profiles
M2 - Wed Sep 23, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/x5k9pd/hodgkin_lymphoma) has announced the addition of the "Hodgkin Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hodgkin Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hodgkin Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - 4SC AG - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - ADC Therapeutics Sarl - Affimed Therapeutics AG - Aptose Biosciences Inc. - Arbutus Biopharma Corporation - AVEO Pharmaceuticals, Inc. - Bellicum Pharmaceuticals, Inc. - Biogenomics Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell Medica Limited - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - Curis, Inc. - Gamida Cell Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Johnson & Johnson - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - Mirati Therapeutics Inc. - Molecular Templates Inc. - NantKwest, Inc. - Novartis AG - Ono Pharmaceutical Co., Ltd. - Pfizer Inc. - Pharmacyclics, Inc. - Philogen S.p.A. - Seattle Genetics, Inc. - Selvita SA - Sigma-Tau S.p.A. - TG Therapeutics, Inc. - Theravectys SA Drug Profiles (Partial List) - abexinostat hydrochloride - Drug Profile - acalisib - Drug Profile - ADCT-301 - Drug Profile - AFM-13 - Drug Profile - Alocrest - Drug Profile - aNK Program - Drug Profile - APTO-253 - Drug Profile - azacitidine - Drug Profile - BMS-986016 - Drug Profile - BPX-501 - Drug Profile - brentuximab vedotin - Drug Profile - CBM-C30.1 - Drug Profile - Cell Therapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas - Drug Profile - Cell Therapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia - Drug Profile - Cell Therapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection - Drug Profile - Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases - Drug Profile - Cell Therapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology - Drug Profile - CMD-003 - Drug Profile - CPI-0610 - Drug Profile - CUDC-907 - Drug Profile - Dendritic Cell Therapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma - Drug Profile - INCB-40093 - Drug Profile - Indimitecan - Drug Profile - Indotecan hydrochloride - Drug Profile - interferon alfa-2b (recombinant) - Drug Profile - Iomab-B - Drug Profile - NSC-678515 - Drug Profile - panobinostat - Drug Profile - pembrolizumab - Drug Profile - pevonedistat hydrochloride - Drug Profile - procarbazine hydrochloride - Drug Profile - radretumab - Drug Profile - Recombinant Proteins for Melanoma and Hodgkin's Lymphoma - Drug Profile - TGR-1202 - Drug Profile - TKM-PLK1 - Drug Profile For more information visit http://www.researchandmarkets.com/research/x5...n_lymphoma
CRIS: 1.69 (-0.10), PCYC: 261.25 (+1.70), PFE: 35.29 (-0.02), INCY: 80.41 (-1.20), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), ABUS: 3.60 (-0.33), JNJ: 117.01 (+0.01), APTO: 2.96 (-0.12), ATNM: 1.82 (unch), BLCM: 12.91 (-0.03), SGEN: 40.38 (-0.63), GILD: 84.45 (-1.32), MRK: 56.81 (-0.37), AVEO: 1.03 (-0.03), MRTX: 8.09 (-1.53), CBMG: 15.16 (+0.22), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Mirati Therapeutics prices public offering of 2.25m common stock
M2 - Wed Sep 16, 4:34AM CDT
Cancer treatment company Mirati Therapeutics (NasdaqCM:MRTX) said on Tuesday that it has priced an underwritten public offering of 2,250,000 shares of its common stock.
MRTX: 8.09 (-1.53)
